Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors

Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors

US Patent 10501467 · Granted Dec 10, 2019

Estimated economic value: $95,456,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Rhizobial tRNA-derived small RNAs and uses thereof for regulating plant nodulati2025
Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist2025
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer2022
Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases2022
Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases2022
Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist2022
Treatment cancers using a combination comprising PARP inhibitors2021
Treatment cancers using a combination comprising PARP inhibitors2021
Treatment cancers using a combination comprising PARP inhibitors2021
Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, a2021
Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, a2021
5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleam2021